PharmaMar Shows New Clinical Data With Yondelis® in Different Sarcoma Subtypes at CTOS 2016
MADRID, November 10, 2016 /PRNewswire/ --
Within the framework of the 21st Annual Meeting of the Connective Tissue Oncology Society (CTOS), that is taking place from the 9th of November until the 12th of November at Lisbon (Portugal), PharmaMar (MCE:PHM) is going to present the clinical data for the treatment of sarcomas obtained from various studies carried out with Yondelis® (trabectedin).
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
In this sense, it will be published, among others, the data from the Phase II randomized, non-comparative, TAUL study, that assess the activity of Yondelis® in patients with metastatic or locally relapsed uterine leiomyosarcoma; the TR1US study that evaluates trabectedin as first line treatment, in advanced soft tissue sarcoma (STS) patients unfit to receive standard anthracycline-based chemotherapy; and the YonLife trial that studies the quality of life reported by the patients with STS who receive Yondelis®. All of these studies have received financial support from PharmaMar.
"PharmaMar continues to support the clinical development of trabectedin for the treatment of soft tissue sarcomas and to generate data on the efficacy and safety of Yondelis® in almost all subtypes, which are mainly rare and difficult to treat", explains Dr Nadia Badri, VP of Medical Affairs of the Oncology Business Unit at PharmaMar. "The role of trabectedin to treat patients with STS is still increasing as well as preclinical research to better understand the unique mechanism of action of the compound. It is important to note that there will be more than 20 presentations of studies with our drug in the meeting", she adds.
As well as the clinical evidence, PharmaMar will present an abstract on pharmacoeconomics that evaluates, in Spain, the benefit-cost ratio of trabectedin versus pazopanib for the treatment of patients with advanced, metastatic soft tissue sarcoma, after receiving one or two prior lines of chemotherapy.
To finalize, in the symposium entitled ´Rising options in advanced STS: present and future treatment sequences´, the Company will gather a group of oncologists of international prestige to discuss on the necessities of defining the most convenient treatment sequences with the current drugs and for those to come, for patients with advanced STS, with the aim of improving their prognosis and quality of life.
Contact: Paula Fernández, Media Relations, +34-638-79-62-15 or Investor Relations, +34-914444500
Share this article